Stock LXRX LEXICON PHARMACEUTICALS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

News Lexicon Pharmaceuticals, Inc.

Equities

LXRX

US5288723027

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-04-15 pm EDT 		5-day change 1st Jan Change
1.87 USD -5.08% Intraday chart for Lexicon Pharmaceuticals, Inc. -10.53% +22.22%
Mar. 25 Lexicon Pharmaceuticals Files Prospectus for Secondary Offering MT
Mar. 12 Lexicon Pharmaceuticals Shares Decline After Analysis Finds Similar Effect of Sotagliflozin in Type 1 Diabatic Patients MT

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Lexicon Pharmaceuticals to Participate in the 23rd Annual Needham Virtual Healthcare Conference
AQ
Lexicon Pharmaceuticals Files Prospectus for Secondary Offering
MT
Clinical Data on the Impact of Sotagliflozin on Stroke and Heart Attack Risk Among Four Lexicon-Sponsored Presentations at the American College of Cardiology 73rd Annual Scientific Session & Expo
AQ
Lexicon Pharmaceuticals Shares Decline After Analysis Finds Similar Effect of Sotagliflozin in Type 1 Diabatic Patients
MT
New Post Hoc Analysis of inTandem3 Study Demonstrates Improvements In Glycemic Control With Sotagliflozin Treatment in Patients With Type 1 Diabetes and Chronic Kidney Disease
AQ
Lexicon Pharmaceuticals, Inc. Announces New Post Hoc Analysis of Intandem3 Study Demonstrates Improvements in Glycemic Control with Sotagliflozin Treatment in Patients with Type 1 Diabetes and Chronic Kidney Disease
CI
Health Care Dips Amid Regulatory Doubts -- Health Care Roundup
DJ
Sector Update: Health Care Stocks Softer Late Afternoon
MT
Sector Update: Health Care Stocks Decline in Afternoon Trading
MT
Lexicon Pharmaceuticals Q4 Net Loss Widens, Revenue Rises; to Resubmit NDA for Sotagliflozin; Shares Jump
MT
Lexicon Pharmaceuticals Q4 Net Loss Widens, Revenue Rises; to Resubmit NDA for Sotagliflozin; Shares Gain Pre-Bell
MT
Lexicon Pharmaceuticals Shares Rise on Beat to 4Q Loss, Plans for Sotagliflozin
DJ
Lexicon: Q4 Earnings Snapshot
AQ
Earnings Flash (LXRX) LEXICON PHARMACEUTICALS Reports Q4 Revenue $702,000
MT
Lexicon Pharmaceuticals Reports Fourth Quarter 2023 Financial Results and Provides Business Update
AQ
Lexicon Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Lexicon Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023
CI
Lexicon Announces Oversubscribed $250 Million Private Placement of Equity Securities
AQ
Lexicon Preparing to Resubmit Sotagliflozin NDA for Type 1 Diabetes Following Feedback From FDA
AQ
Lexicon Pharmaceuticals, Inc Preparing to Resubmit Sotagliflozin NDA for Type 1 Diabetes Following Feedback From FDA
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. LXRX Stock
  4. News Lexicon Pharmaceuticals, Inc.